Antibodies, also known as immunoglobulins, are specialized proteins produced by the immune system to identify and neutralize foreign invaders, such as viruses, bacteria, and other pathogens. They are ...
The latest Omicron subvariants are evolving to become more immune evasive, rendering monoclonal antibody treatments such as Evusheld and the forthcoming bebtelovimab ineffective against new strains.
Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive global licensing ...
Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or ...
A potential first-in-class therapy for migraine prevention has shown promise in a phase 2a proof-of-concept study, with a single infusion reducing migraine frequency over 4 weeks. The drug Lu AG09222 ...
This first-in-man trial conducted by Onward Therapeutics, under the license and co-development agreement, is a Phase 1 clinical trial for the evaluation of a bispecific antibody generated from ...
The mammalian immune system produces a range of antibody types in order to protect the host from the daily onslaught of foreign invaders. These various antibody classes typically have well-defined ...
In contrast, the experts noted that several recent FDA approvals introduced first-in-class therapies to the oncology landscape. 1 Among these are menin inhibitors, which block the interaction between ...
Numerous variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged since the initial Wuhan-Hu-1 prototype. The new variants evade pre-existing immunity by prompting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback